Q-omics provides the consensus-scored GUCY2F profile across patient tissues and cancer cell-line models. GUCY2F expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GUCY2F is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, GUCY2F RNA expression shows 10,234 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where GUCY2F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCY2F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCY2F survival associations across molecular data types. GUCY2F RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCY2F RNA expression–survival associations across cancer types. High GUCY2F expression shows unfavorable associations in ACC, KIRC, LIHC, KICH and UVM, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GUCY2F RNA expression.
This table summarizes GUCY2F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GUCY2F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCY2F shows lower tumor expression in LUAD, STAD and LUSC and higher tumor expression in LIHC, HNSC and BRCA. The LUAD box plot shows higher GUCY2F RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p = .001).
This table shows molecular features associated with GUCY2F in patient tissues and cancer cell lines. In patient samples, GUCY2F shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCY2F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
